IO Biotech, Inc. (IOBT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (6.41%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.90 0.00 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
IOBT 0.90 +0.05(6.41%)
Will IOBT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IOBT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOBT
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IOBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IOBT
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)
Nasdaq Dips Over 2%; US Construction Spending Falls In July
IO Biotech price target lowered by $3 at Morgan Stanley, here's why
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA? (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech says IDMC recommends continuation of IO102-IO103 trial